Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ CRABP2 Polyclonal Antibody
Rabbit Polyclonal Antibody
Supplier: Invitrogen™ PA582140
Description
Immunogen sequence: IKQEGDTFYI KTSTTVRTTE INFKVGEEFE EQTVDGRPCK SLVKWESENK MVCEQKLLKG EGPKTSWTRE LTNDGELILT MTADDVVCTR VYVRE.
Cellular retinoic acid binding protein (CRABP) is a low molecular weight protein with unknown function and existing in two isoforms, CRABP1 and CRABP2. The predicted amino acid sequences of human CRABP1 and CRABP2 exhibits 99.3 and 93.5% identity to mouse CRABP1 and CRABP2, respectively. The CRABP2 isoform is important in retinoic acid-mediated regulation of human skin growth and differentiation. The CRABP2 gene localized on human chromosome 1q21.3 is transcriptionally regulated by a newly synthesized regulatory protein. The protein is expressed in human adult liver.
Specifications
CRABP2 | |
Polyclonal | |
Unconjugated | |
CRABP2 | |
AI893628; cellular lipid-binding protein; cellular retinoic acid binding protein 2; cellular retinoic acid binding protein II; cellular retinoic acid-binding protein 2; Cellular retinoic acid-binding protein II; Crabp2; Crabp-2; CrabpII; CRABP-II; RBP6; RP11-66D17.4 | |
Rabbit | |
Antigen Affinity Chromatography | |
RUO | |
1382 | |
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles. | |
Liquid |
Immunohistochemistry (Paraffin), Western Blot, Immunocytochemistry | |
0.1 mg/mL | |
PBS with 40% glycerol and 0.02% sodium azide; pH 7.2 | |
P29373 | |
CRABP2 | |
Recombinant protein corresponding to Human CRABP2. Recombinant protein control fragment (Product #RP-96785). | |
100 μL | |
Primary | |
Human | |
Antibody | |
IgG |
Safety and Handling
WARNING: Cancer - www.P65Warnings.ca.gov
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction